RET and lung cancer: The Archer® FusionPlex®ALK, RET, ROS1 v2 allowed the expected detection of the fusion breakpoints present in the samples: EML4-ALK (E6:A20) and CCDC6-RET (C1:R12) for the commercialized sample, and EML4-ALK (E6:A20) for the human lung cancer cell line H2228.